Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease

New England Journal of Medicine

Volumn 353, Issue 9, 2005, Pages 898-908

  Reid, Ian R ^a   Miller, Paul ^b   Lyles, Kenneth ^c   Fraser, William ^d   Brown, Jacques P ^e   Saidi, Youssef ^f   Mesenbrink, Peter ^f   Su, Guoqin ^f   Pak, Judy ^f   Zelenakas, Ken ^f   Luchi, Monica ^f   Richardson, Peter ^f   Hosking, David ^g  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b University of Colorado Health Sciences Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e LAVAL UNIVERSITY   (Canada)

^f NOVARTIS PHARMA AG   (Switzerland)

^g NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; RISEDRONIC ACID; ZOLEDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DRUG DERIVATIVE; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH SURVEY; HUMAN; HYPOCALCEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PAGET BONE DISEASE; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BLOOD; BONE; BONE REMODELING; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; DIPHOSPHONATES; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; OSTEITIS DEFORMANS; QUALITY OF LIFE;

EID: 24044431619     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa044241     Document Type: Article

References (25)

1. Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000;15:461-5.
2. Cooper C, Schafheutle K, Dennison E, Kellingray S, Guyer P, Barker D. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999;14:192-7.
3. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996;101:341-8. [Erratum, Am J Med 1997;102:322.]
4. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999;106:513-20.
5. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
6. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
7. Nancollas GH, Tang R, Gulde S, Ebetino FJ, Phipps RJ, Russell RGG. Mineral binding affinities and zeta potentials of bisphosphonates. J Bone Miner Res 2002;17:Suppl 1:S368. abstract.
8. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
9. Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 1998;41:354-60.
10. Ware JE Jr, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: Health Institute, 1994.
11. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996;81:961-7.
12. Singer FR, Clemens TL, Eusebio RA, Bekker PJ. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 1998;83:1906-10.
13. Reginster JY, Colson F, Morlock G, Combe B, Ethgen D, Geusens P. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum 1992;35:967-74. [Erratum, Arthritis Rheum 1993;36:134.]
14. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995;38:851-8.
15. Fraser WD, Stamp TC, Creek RA, Sawyer JP, Picot C. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J 1997;73:496-502.
16. Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004;35:224-30.
17. Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 1997;60:415-8.
18. Buckler H, Fraser W, Hosking D, et al. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone 1999;24:Suppl 5:81S-85S.
19. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
20. Bauss F, Russell RGG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423-33.
21. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002;55:210-24.
22. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999;14:Suppl 2:53-65.
23. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 1987;295:1301-5.
24. Fenton AJ, Gutteridge DH, Kent GN, et al. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol (Oxf) 1991;34:197-204.
25. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003;348:1503-4.